oral+semaglutide+approval The FDA has just approved the first GLP‑1 pill for obesity: a once‑daily oral semaglutide “Wegovy pill,” which offers weight loss similar to the injectable Wegovy and also reduces cardiovascular risk in A new class of oral

Unlike Zepbound and Mounjaro, which are classified as GIP/GLP-1 receptor agonists, Ozempic is classified as only a GLP-1 receptor agonist

According to the Phase 2 trial published in the New England Journal of Medicine , retatrutide achieved weight reductions up to 24.2% at 48 weeks , with projections nearing or exceeding 25% at full duration (Coskun et al., 2023)

Clinical trials employing ambulatory blood pressure monitoring documented small, transient increases in systolic blood pressure (2-3 mmHg) and reductions in heart rate occurring 0-4 hours post-dose

Anecdotal reports suggest more variable outcomes

Changes in FBG, HbA1c, and HOMA-IR were significantly correlated with intervention time in a nonlinear fashion

An ACC press release in 2024 reported that stimulant prescriptions were associated with an increased likelihood of developing cardiomyopathy in young adults, with an estimated absolute risk of about 1 in 2,000 per year or roughly 1 in 500 over 10 years